All. 07_ mod. curriculum europeo

F O R M A T O E U R O P E O
P E R I L C U R R I C U L U M
INFORMAZIONI PERSONALI
ESPERIENZA LAVORATIVA
• Date (da – a) 2002-2006
• Nome e indirizzo del datore di Dipartimento di Medicina clinica e Biotecnologia applicata “D. Campanacci” – Via Massarenti 9 –
• Tipo di azienda o settore Alma Mater Studiorum Università di Bologna
• Tipo di impiego Dottorando di Ricerca – Assegnista di Ricerca
• Principali mansioni e responsabilità At ività di ricerca clinica
• Date (da – a) 2007-2011
• Nome e indirizzo del datore di Dipartimento di Medicina Interna, dell’Invecchiamento e Malattie nefrologiche – Via Massarenti 9
• Tipo di azienda o settore Alma Mater Studiorum Università di Bologna
• Tipo di impiego Assegnista di Ricerca
• Principali mansioni e responsabilità At ività di ricerca clinica
• Nome e indirizzo del datore di Dipartimento di Medicina Interna, dell’Invecchiamento e Malattie nefrologiche – Via Massarenti 9 • Tipo di azienda o settore Alma Mater Studiorum Università di Bologna • Tipo di impiego Ricercatore universitario – SSD Med09 (Medicina Interna) • Principali mansioni e responsabilità At ività di ricerca clinica ISTRUZIONE E FORMAZIONE
• Nome e tipo di istituto di istruzione Corso di Laurea in Medicina e Chirurgia – Facoltà di Medicina e Chirurgia – Alma Mater Studiorum Università di Bologna (Voto di laurea 110/110 e lode) • Principali materie / abilità Medicina e Chirurgia • Qualifica conseguita Medico Chirurgo • Nome e tipo di istituto di istruzione Scuola di specializzazione in Farmacologia ad indirizzo clinico – Facoltà di Medicina e Chirurgia – Università degli Studi di Modena e Reggio nell’Emilia (Voto di specializzazione 110/110 e lode • Principali materie / abilità Farmacologia clinica e tossicologia medica • Qualifica conseguita Specialista in Farmacologia clinica Pagina 1 - Curriculum vitae di Arrigo F.G. Cicero • Nome e tipo di istituto di istruzione Dottorato di ricerca in Medicina Sperimentale Aterosclerosi – Facoltà di Medicina e Chirurgia – • Principali materie / abilità Metodiche sperimentali in medicina, con particolare attenzione all’ambito dell’aterosclerosi e • Qualifica conseguita Dottore di Ricerca in Medicina Sperimentale Aterosclerosi CAPACITÀ E COMPETENZE
PERSONALI
PRIMA LINGUA Italiano
Francese Inglese Tedesco
• Capacità di lettura Ot ima Molto buona Sufficiente
• Capacità di scrit ura Buona Buona Sufficiente
• Capacità di espressione orale Ot ima Buona Sufficiente
CAPACITÀ E COMPETENZE COMPETENZE DIDATTICO-DIVULGATIVE ACCERTATE IN LEZIONI UNIVERSITARIE, CORSI, SEMINARI E MASTERS RIVOLTI A STUDENTI, MEDICI, FARMACISTI, ERBORISTI, ETC Coordinazione di studi (anche multicentrici) e di gruppi di ricerca in ambito universitario CAPACITÀ E COMPETENZE Esperienze organizzative come segretario scientifico in diversi corsi e convegni, nazionali ed internazionali in ambito medico-scientifico; Esperienze di gestione finanziaria di fondi finalizzati CAPACITÀ E COMPETENZE Impiego corrente di Word, Excel , Power Point, Access, SPSS, Primer ULTERIORI INFORMAZIONI - Autore di oltre 200 pubblicazioni scientifiche integrali su stampa internazionale
(IF>390, h-index= 24), 50 pubblicazioni scientifiche integrali su stampa nazionale, 2 trattati e 180 estrat i pubblicati su at i di congressi nazionali ed internazionali. - At ività di tipo didat ico-divulgativo in ambito medico-scientifico a corsi e seminari nazionali ed internazionali (ca. 40/anno) - Ruolo di organizzatore e/o coordinatore di corsi ed eventi accreditati ECM - At ività di referee per diverse riviste scientifiche internazionali nel ’ambito del e malat ie del metabolismo, del a nutrizionistica e del a farmacoterapia ALLEGATI
ELENCO PUBBLICAZIONI SU STAMPA INTERNAZIONALE CON IF Il sottoscritto è a conoscenza che, ai sensi dell’art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l’uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla --------------------------------
Pagina 2 - Curriculum vitae di Arrigo F.G. Cicero Pubblicazioni integrali su stampa internazionale con IF (N. 151) IF>370; h-index= 18
• Cicero AFG, Bandieri E, Arletti R. Orally administered Panax notoginseng influences rat spontaneous behaviour. Journal of Ethnopharmacology (J
Ethnopharmacol) 2000; 73: 387-391.
• Cicero AFG, Braiato A, D’Addato S, Sangiorgi Z, Gaddi A. A suggestion for Familial Hypercholesterolemia (FH) heterozygosity clinical diagnosis
based on an epidemiological observation in a large Italian population. International Journal of Cardiology (Int J Cardiol) 2000; 74: 5-11.
• Gaddi A, Berto P, Mussoni C, Cicero AFG, D’Addato S, Cantagalli F. Antihyperlipidaemic drugs: the results of a Drug Utilisation Review (DUR)
research in the Bologna area. Clinical Drug Investigation (Clin Drug Invest) 2000; 19(6): 457-464.
• Cicero AFG, Bandieri E, Arletti R. Lepidium meyenii Walp. improves sexual behaviour in male rats independently from its action on spontaneous
locomotor activity. Journal of Ethnopharmacology (J Ethnopharmacol) 2001; 75(2-3): 225-229.
• Cicero AFG, Gaddi A. Rice Bran oil and 
-oryzanol in the treatment of hyperlipoproteinemias and other conditions. Phytotherapy Research (Phytother Res) 2001; 15(4): 277-289. [Review]
• Cicero AFG, Martini C, Fiorito A, Gaddi A. Case Problem: Dietary treatment for children with hyperlipidemia. Journal of the American Dietetic
Association (J Am Diet Ass) 2001; 101: 693-696.
• Gaddi A, Cicero AFG, Dormi A, Pasquarelli V, D'Addato S. The realisation of a project aimed at reducing the plasmatic lipid level in a large Italian
rural population improves the mean calcium daily intake: the Brisighella Study (BS). European Journal of Clinical Nutrition (Eur J Clin Nutr) 2001; 55(2): 97-106.
• Pini LA, Cicero AFG, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesics overuse. Cephalalgia 2001;21:878-83
• Pini LA, Cicero AFG. Triptans: the experience of a clinical pharmacologist in clinical practice. Journal of Headache and Pain (J Headache Pain) 2001;
2(S1): 103-106.
diastolic and pulse pressure as risk factors for cardiovascular events in the Brisighella Heart Study. Journal of Hypertension (J Hypertens) 2002; 20(9):1737-1742.
• Cicero AFG, Fiorito A, Panourgia MP, Sangiorgi Z, Gaddi A. Ef ects of a new soy/
-sitosterol supplement on plasma lipids in moderately hypercholesterolemic subjects. Journal of the American Dietetic Association (J Am Diet Ass) 2002; 102(12): 1807-1811.
• Cicero AFG, Piacente S, Plaza A, Sala E, Arletti R, Pizza C. Hexanic Maca extract improves rat sexual performance more effectively than methanolic
and chloroformic Maca extracts. Andrologia 2002; 34(3): 177-179.
• Gaddi A, Cicero AFG, Poli A, Nascetti S, Inzitari D on behalf of the Italian Study Group for the study of Dysmetabolic Diseases and Atherosclerosis.
Cerebrovascular disease in Italy and Europe: it is necessary to prevent a pandemia. Journal of Cardiovascular Risk (J Cardiovasc Risk) 2002;9:1-3
• Pini LA, Cicero AFG, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesics overuse [Author’s reply]. Cephalalgia
2002; 22: 327-328.
• Borghi C, Dormi A, L'Italien G, Lapuerta P, Franklin SS, Collatina S, Gaddi A on behalf of the Brisighella Heart Study working party (in which Cicero
AFG). The relationship between systolic blood pressure and cardiovascular risk--results of the Brisighella Heart Study. Journal of Clinical
Hypertension (J Clin Hypertens) 2003; 5(1): 47-52.
• Cicero AFG, Derosa G, Gaddi A. Homocysteine and cardiovascular risk. Journal of Headache and Pain (J Headache Pain) 2003; 4(3): 171-172.
• Cicero AFG, Fiorito A, Rontini T, Nascetti S, Sangiorgi Z, Dormi A, Gaddi A. Dietary habits did not influence plasma antibodies against oxidized LDL
level in a wide sample of healthy subjects: the Brisighella Heart Study. Vaccine 2003; 21(S 2):S35-S37.
• Cicero AFG, Forghieri M, Arletti R. Hypercholesterolemia underdiagnosis and undertreatment in psychiatric patients in Italy. European Journal of
Epidemiology (Eur J Epidemiol) 2003; 18: 373-374.
• Cicero AFG, Panourgia MP, Linarello S, D’Addato S, Sangiorgi Z, Gaddi A. Serum lipoprotein(a) levels in a large sample of subjects affected by
familial combined hyperlipoproteinemia (FCH) and in general population. Journal of Cardiovascular Risk (J Cardiovasc Risk) 2003; 10(2): 149-151.
• Cicero AFG, Panourgia MP, Nascetti S, Sangiorgi Z, Gaddi A. Asymptomatic massive hypertriglyceridemia in an octogenarian. Medicine Principles
and Practice (Med Princ Pract) 2003; 12: 51-53.
• Cicero AFG, Vitale G, Savino G, Arletti R. Panax notoginseng (Burk.) effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet.
Phytotherapy Research (Phytother Res) 2003; 17(2): 174-178.
• Derosa G, Cicero AFG, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. A randomized, double-blind, controlled parallel-group comparison of perindopril
and candesartan in hypertensive patients with type 2 diabetes mellitus. Clinical Therapeutics (Clin Ther) 2003; 25(7): 2006-2021.
• Derosa G, Cicero AFG, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic
patients with type 2 diabetes mellitus. Clinical Therapeutics (Clin Ther) 2003; 25(5): 1429-1439.
• Derosa G, Cicero AFG, Mugellini A, Ciccarelli L, Fogari R. Perindopril and Candesartan comparative efficacy and safety in type 2 diabetic
hypertensive patients. Journal of Human Hypertension (J Hum Hypert) 2003; 17(6): 433-435.
• Gaddi A, Cicero AFG, Nascetti S, Poli A, Inzitari D on behalf of the Italian Study Group for the study of Dysmetabolic Diseases and Atherosclerosis.
Cerebrovascular disease in Italy and Europe: it is necessary to prevent a "pandemia". Gerontology 2003; 49(2): 69-79. [Review]
• Gaddi A, Poli A, Cicero AFG, Inzitari D on behalf of the Italian Study Group for the study of Dysmetabolic Diseases and Atherosclerosis. It is
necessary to prevent a cerebrovascular "pandemia". Cerebrovascular Disease (Cerebrovasc Dis) 2003; 15(1-2): 152-153. [Letter]
• Sternieri E, Ferrari A, Cicero AFG. Clinical considerations preliminary to the application of the Italian Society for the Study of Headache Guidelines
regarding the Migraine Prophylactic Treatment. Journal of Headache and Pain (J Headache Pain) 2003; 4(1): 14-17. [Editorial]
• Borghi C, Dormi A, D’Addato S, Gaddi A, Ambrosioni E on behalf of the Brisighella Heart Study Working Party (in which Cicero AFG). Trends in blood
pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. Journal of Hypertension (J Hypert) 2004; 22: 1707–
• Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A on behalf of the Brisighella Heart Study Working Party (in which Cicero AFG). Association
between dif erent lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. American Heart Journal (Am Heart J) 2004; 148: 285–292.
• Cicero AFG, Derosa G, Arletti R. Ef ect of oral chronic isoflavones supplementation on male rat sexual performances and sexual hormone plasma
levels. Phytotherapy Research (Phytother Res) 2004; 18: 849-852.
• Cicero AFG, Derosa G, Bril ante R, Mirembe S, Nascetti S, Gaddi A. Ef ects of Siberian ginseng (Eleutherococcus senticosus maxim.) on elderly
quality of life: a randomized clinical trial. Archives of Geriatrics and Gerontology (Arch Geriatr Gerontol) 2004; 38S: 69-73.
Pagina 3 - Curriculum vitae di Arrigo F.G. Cicero • Cicero AFG, Derosa G, Gaddi A. What herbalists suggest to our diabetic patients in order to improve their glycaemic control? Evaluation of scientific
evidences and potential risks. Acta Diabetologica (Acta Diabetol) 2004; 41(3): 91-98.
• Cicero AFG, Minardi M, Mirembe S, Pedro E, Gaddi A. Ef ects of a new low dose soy protein/ 
-sitosterol association on plasma lipid levels and oxidation. European Journal of Nutrition (Eur J Nutr) 2004; 43(5): 319-322.
• Derosa G, Cicero AFG, Bertone G, Piccinni MN, Fogari E, Ciccarelli L, Fogari R. Comparison of the effects of telmisartan and nifedipine
gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clinical Therapeutics (Clin Ther) 2004; 26(8): 1228-1236.
• Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinini MN. Metabolic effects of Pioglitazone and Rosiglitazone in
patients with diabetes and metabolic syndrome treated with Glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel- group trial. Clinical Therapeutics (Clin Ther) 2004; 26(5): 744-754.
• Derosa G, Cicero AFG, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic
obese patients. Diabetes Nutrition and Metabolism (Diab Nutr Metab) 2004; 17(4): 222-230.
• AFGComparison of fluvastatin + fenofibrate combination therapy and fluvastatin
monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double- blind, controlled trial. Clinical Therapeutics (Clin Ther) 2004; 26(10): 1599-607.
• Ferrari A, Pasciullo G, Savino G, Cicero AFG, Ot ani A, Bertolini A, Sternieri E. Headache treatment before and after the consultation of a specialized
centre: a pharmacoepidemiology study. Cephalalgia 2004; 24(5): 356-362.
• Gaddi A, Cicero AFG, Pedro E. Clinical perspectives of anti-inflammatory therapy in the elderly: the Lox-/Cox- inhibition concept. Archives of
Geriatrics and Gerontology (Arch Geriatr Gerontol) 2004; 38(3): 201-212. [Review]
• Cicero AFG, Derosa G. Rice bran and its main components: potential role in the management of cardiovascular disease risk. Current Topics in
Nutraceutical Research (Curr Topics Nutraceut Res) 2005;3(1): 29-46.
• Cicero AFG, Derosa G, Gaddi A. Combined Lipoxygenase/Cicloxygenase inhibition in the elderly: the example of Licofelone. Drug Aging 2005; 22(5):
• Cicero AFG, Derosa G, Gaddi A. Statin and IMT. Diabetes Care (Diab Care) 2005; 28(5): 1262-1263. [Letter]
• Cicero AFG, Derosa G, Miconi A, Laghi L, Nascetti S, Gaddi A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant
to PUFA and fibrates. Biomedicine & Pharmacotherapy (Biomed Pharmacother) 2005; 59: 312-317.
• Cicero AFG, Brancaleoni M, Laghi L, Donati F, Mino M. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large
sample of subjects at low risk for cardiovascular disease: a pilot study. Complementary Therapy in Medicine (Complem Ther Med) 2005; 13: 273-78
• Cicero AFG, Derosa G, Miconi A, Laghi L, Nascetti S, Gaddi A. Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible
role for the coenzyme Q10? BioFactors 2005; 23: 7-14.
• Cicero AFG, Dormi A, Nascetti S, D’Addato S, Gaddi A. Relative role of major risk factors for Type 2 Diabetes development in the historical cohort of
the Brisighella Heart Study: an 8-years follow-up. Diabetic Medicine (Diabetic Med) 2005; 22: 1263-1266.
• Cicero AFG, Gaddi A. REVERSAL and PROVE-IT: are clinically oriented trials really better than “pure” scientific studies? International Journal of
Cardiology (Int J Cardiol) 2005; 103: 135-137. [Editorial]
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertension Research (Hypertens Res) 2005; 28(11): 917-924
• f ects of Doxazosin and Irbesartan on Blood Pressure and Metabolic Control in Patients with Type 2 Diabetes and Hypertension. Journal of Cardiovascular Pharmacology (J Cardiovasc Pharmacol) 2005; 45(6): 599-604.
• Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. A comparison of the effects of Pioglitazone
and Rosiglitazone combined with Glimepiride on prothrombotic state in patients with the metabolic syndrome. Diabetes Research and Clinical Practice (Diab Res Clin Pract) 2005; 69: 5-13.
• Derosa G, Cicero AFG, Gaddi AV, Ciccarelli L, Picinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R. Long-term effects of
glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clinical Therapeutics (Clin Ther) 2005; 27(9): 1383-1391.
• Derosa G, Cicero AFG, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. Ef icacy and safety comparative evaluation of orlistat
and sibutramine treatment in hypertensive obese patients. Diabetes, Obesity and Metabolism (Diabetes Obes Metab) 2005; 7(1): 47-55.
• Derosa G, Gaddi A, Piccinnni MN, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AFG. Antithrombotic effects of combination rosiglitazone-
metformin vs. combination glimepiride-metformin therapy in patients with type 2 diabetes and metabolic syndrome. Pharmacotherapy 2005; 25(5):
• Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. Journal of International Medical Research (J Int Med Res) 2005; 33(3): 284-294.
• Ferrari A, Ot ani A, Bertolini A, Cicero AFG, Coccia CPR, Leone S, Sternieri E.Adverse reactions related to drugs for headache treatment: clinical
impact. European Journal of Clinical Pharmacology (Eur J Clin Pharmacol) 2005; 60:893-900.
• Borghi C, Cicero AFG. Recent evidences of the role of 
-3 polyunsaturated fatty acids on blood pressure control and hypertension related complication. Future in Lipidology (Future Lipidol) [actually Clinical Lipidology] 2006; 1(5): 569-577.
• Cicero AFG, Nascetti S, Noera G, Gaddi AV for the Massalombarda Project Team. Metabolic Syndrome prevalence in Italy. Nutrition Metabolism and
Cardiovascular Disease (Nutr Metab Cardiovasc Dis) 2006; 16(6): e5-6.
• Derosa G, Cicero AFG, D'Angelo A, Tinelli C, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Ghelfi M, Gravina A, Ferrari I, Gal i S,
Paniga S, Fogari R. Ef ect of doxazosin on C-reactive protein plasma levels in patients with hypertension. Journal of Cardiovascular Pharmacology (J Cardiovasc Pharmacol) 2006; 47(4): 508-512.
irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertension Research (Hypertens Res) 2006; 29(11): 849-856.
of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes Pagina 4 - Curriculum vitae di Arrigo F.G. Cicero mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clinical Therapeutics (Clin Ther) 2006; 28(5): 679-
• Derosa G, Cicero AFG, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Ferrari I, Gravina A, Fogari R. Synergistic effect
of doxazosin and acarbose in improving metabolic control in subjects with impaired glucose tolerance. Clinical Drug Investigation (Clin Drug Invest) 2006; 26(9): 529-539.
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertensi 13(3): 227-231.
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of Clinical Pharmacy and Therapeutics (J Clin Pharm Ther) 2006; 31(4): 375-383.
Ef ects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. Journal of International Medical Research (J Int Med Res) 2006; 34(5): 545-555.
• Derosa G, Gaddi AV, Piccinni MN, Bertone G, Ciccarelli L, Fogari E, Guelfi M, Ferrari I, Cicero AFG. Dif erential effect of Glimepiride and
Rosiglitazone on metabolic control of Type 2 diabetic patients treated with Metformin: a randomised, double-blind, clinical trial. Diabetes, Obesity and Metabolism (Diabetes Obes Metab) 2006; 8(2): 197-205.
• Derosa G, Salvadeo S, Cicero AFG. Prospects for the development of novel anti-hyperlipidemic drugs. Current Opinion in Investigational Drugs (Curr
Opin Invest Drugs) 2006; 7(9): 826-833. [Review]
• eed for analgesics/drugs of abuse: a comparison between headache patients and addicts by the Leeds Dependence questionnaire (LDQ). Cephalalgia 2006; 26(2): 187-193
• Manca M, Rusticali F, Gaddi AV, Cicero AFG. Physical activity, exercise and cardiovascular health. Future in Lipidology (Fut Lipidol) [actually Clinical
Lipidology] 2006; 1(5): 513-516.
• Micali S, Sighinolfi MC, De Stefani S, Grande M, Cicero AFG, Bianchi G. Can Phyl antus niruri (Uriston ®) affect the efficacy of extracorporeal shock
wave lithiotrispy or renal stones. A randomised, prospective, long-term study. Journal of Urology (J Urol) 2006; 176(3): 1020-1022.
• Sighinolfi MC, Mofferdin A, De Stefani S, Celia A, Micali S, Cicero AFG, Bianchi G. Changes in peak systolic velocity induced by chronic therapy with
phosphodiesterase type 5 inhibitor. Andrologia 2006; 38(3): 84-86.
Albuminuria, NAG Excretion and Glomerular Filtration Response to Dopamine in Diabetic Patients.
2006; 26(6): 621-628.
• Interaction between serum cholesterol levels and the renin- angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure. Journal of Hypertension (J Hypertens) 2007;25(10):2051-2057.
• Bove M, Cicero AFG, Manca M, Georgoulis I, Motta R, Giovannini M, Poggiopollini G, Gaddi AV. Sources of variability of plasma HDL-cholesterol
levels. Future in Lipidology (Fut Lipidol) [actually Clinical Lipidology] 2007; 2(5): 557-569.
• Cicero AFG, Derosa G, Manca M, Bove M, Borghi C, Gaddi AV. Manuscript Title: Vascular remodelling and prothrombotic markers in subjects
affected by Familial Combined Hyperlipidemia and/or Metabolic Syndrome in primary prevention for cardiovascular disease. Endothelium 2007; 14(4):
• Cicero AFG, Bove M, Manca M, Borghi C, Gaddi AV. Detection of Familial Combined Hyperlipoproteinemia patients in the Brisighella Heart Study
historical cohort: an epidemiological approach. Journal of Inherited Metabolic Diseases (J Inherit Metab Dis) 2007; 30(2): 268.
• Cicero AFG, Derosa G, Manca M, Bove M, Borghi C, Gaddi AV. Dif erent effect of psyl ium and guar dietary supplementation on blood pressure
control in hypertensive overweight patients: a 6-month, randomized clinical trial. Clinical Experimental Hypertension (Clin Exp Hypert) 2007;29:1-12
• Cicero AFG, Rovati L, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents
in humans. Arzneimit elforschung/Drug Research 2007; 57(1): 26-30.
• Derosa G, Cicero AFG, D’Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R. Metabolic and antihypertensive effects of
moxonidine and moxonidine plus irbesartan on diabetic hypertensive patients: a sequential, double-blind, randomized clinical trial. Clinical Therapeutics (Clin Ther) 2007; 29(4): 602-610.
Diabetic and Nondiabetic Subjects during Acute Coronary Syndromes. Endothelium 2007; 14(1): 45-51.
• Metalloproteinases in diabetics and non diabetics during acute coronary syndromes and after 3 months. Endothelium. 2007; 14(4): 175-183.
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal (Intern Med J) 2007; 37(2): 79-86.
• f ects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Internal Medicine (Intern Med) 2007;46(22):
• Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart and Vessels (Heart Vessel) 2007; 22(6): 361-370.
and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertension Research (Hypertens Res) 2007; 30(5): 387-94.
Derosa G, Fogari E, D'Angelo A, Cicero AFG, Salvadeo SAT, Ragonesi PD, Ferrari I, Gravina A, Fassi R, Fogari R. Metabolic effects of telmisartan
and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitaz 2): 261-268.
and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes et Metabolism (Diabetes Metab) 2007; 33(2): 129-134.
• Prandin MG, Cicero AFG, Veronesi M, Cosentino E, Dormi A, Strocchi E, Claudio Borghi. Persistence on treatment and blood pressure control with
dif erent first-line antihypertensive treatments: A prospective evaluation. Clinical & Experimental Hypertension (Clin Exp Hypert) 2007;29(8):553-62
Pagina 5 - Curriculum vitae di Arrigo F.G. Cicero • Immediate improvement in penile hemodynamics after cessation of smoking: previous results. Urology 2007; 69(1): 163-165.
• Cicero AFG, Nascetti S, López-Sabater MC, Elosua R, Salonen JT, Nyyssönen K, Poulsen HE, Zunft HJF, Kiesewetter H, de la Torre K, Covas MI,
Kaikkonen J, Mursu J, Koenbick C, Bäumler H, Gaddi AV for the EUROLIVE Study Group. Changes in LDL fatty acid composition as a response to olive oil treatment are inversely related with the lipid oxidative damage: the EUROLIVE Study. Journal of the American College of Nutrition (J Am Coll Nutr) 2008; 27(2): 314-320.
• Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism. 2008; 57(11): 1552-1557.
metalloproteinase-2 and -9 levels in obese patients 15(4): 219-224.
therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Archives of Medical Research (Arch Med Res) 2008; 39(4): 412-419.
• Poli A, Marangoni F, Paoletti R, Mannarino E, Lupattelli G, Notarbartolo A, Aureli P, Bernini F, Cicero AFG, Gaddi AV, Catapano A, Cricelli C,
Gattone M, Marrocco W, Porrini M, Stella R, Vanotti A, Volpe M, Volpe R, Cannella C, Pinto A, Del Toma E, La Vecchia C, Tavani A, Manzato E, Riccardi G, Sirtori C, Zambon A; Nutritional Foundation of Italy. Non-pharmacological control of plasma cholesterol levels. Nutrition Metabolism and Cardiovascular Disease (Nutr Metab Cardiovasc Dis) 2008; 18: S1-S16.
• Borghi C, Cicero AFG, Bacchelli S, Degli Esposti D, Ambrosioni E on behalf of the Survival of Myocardial Infarction Long-term Evaluation (SMILE)
Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post-hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) trial. Fundamental and Clinical Pharmacology (Fund Clin Pharmacol) 2009; 23(5):
• Cicero AFG, Derosa G, Bove M, Di Gregori V, Gaddi AV, Borghi C. Ef ect of a sequential training program on inflammatory, prothrombotic and
vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. European Journal of Cardiovascular Prevention and Rehabilitation (Eur J Cardiovasc Prev Rehab) 2009; 16(6): 698-704
• Cicero AFG, Derosa G, D'angelo A, Bove M, Gaddi AV, Borghi C.
lood Pressure (Blood Press) 2009; 18(3): 111-116.
• Cicero AFG, Derosa G, Gaddi AV. Re: The influence of statin medications on Prostate Specific Antigen levels. Journal of National Cancer Institute (J
Natl Cancer Inst) 2009; 101(8): 610 [Letter]
• Cicero AFG, Derosa G, Bove M, Imola F, Borghi C, Gaddi AV. Long-term effectiveness and safety of a nutraceutical based approach to reduce
cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Current Topics in Nutraceutical Research (Curr Topics Nutrac Res) 2009; 7(3-4): 121-126.
• Cicero AFG, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clinical Lipidology (Clin
Lipidol) 2009; 4(5): 553-563
• Cicero AFG, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Current
Vascular Pharmacology (Curr Vasc Pharmacol) 2009; 7(3): 330-337. [Review]
• Cicero AFG, Veronesi M, Prandin MG, Di Gregori V, Ambrosioni E, Borghi C. Ef ects of AT1 receptor and beta1 receptor blocking on blood pressure,
peripheral hemodynamic and lipid profile in statin treated hypertensive hypercholesterolemic patients. Fundamental and Clinical Phamacology (Fund Clin Pharmacol) 2009; 23(5): 583-8.
• Derosa G, D’Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AFG. Ef icacy and safety of
ezetimibe/simvastatin association on non diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. Journal of ClinicalPharmacy and Therapeutics (J Clin Pharm Ther) 2009; 34(3): 267–276.
• Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AFG
ournal of Clinical Pharmacy and Therapeutics (J Clin Pharm Ther) 2009;34(1):13-23.
• Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AFG
Biomedicine Pharmacotherapy (Biomed Pharmacother) 2009; 63(10): 723-33.
• Derosa G, Ferrari I, Cicero AFG. Irbesartan and hydrochlorothiazide association in the treatment of hypertension. Current Vascular Pharmacology
(Curr Vasc Pharmacol) 2009; 7(2): 120-136. [Review]
• Derosa G, Ferrari I, D'Angelo A, Salvadeo SA, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AFG
eart Vessels. 2009; 24(3): 204-210.
• Derosa G, Maffioli P, D’Angelo A, Salvadeo SAT, Ferrari I, Fogari E, Mereu R, Gravina A, Palombo I, Randazzo S, Cicero AFG. Effects of insulin
therapy with continuous subcutaneous insulin infusion (CSI ) in diabetic patients: conmparison with multi-day insulin injections therapy (MDI). Endocrine Journal (Endocr J) 2009; 56 (4): 571-578
• Derosa G, Maffioli P, D'Angelo A, Salvadeo SAT, Ferrari I, Fogari E, Gravina A, Mereu R, Randazzo S, Cicero AFG. Ef ects of long chain ω-3 fatty
acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. Expert Opinion in Pharmacotherapy (Exp Opin Pharmacother) 2009; 10(8): 1239-47.
• Derosa G, Maffioli P, D'Angelo A, Salvadeo SAT, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Randazzo S, Cicero AFG
linical & Investigational Medicine (Clin Invest Med) 2009;32(2):E124
• Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AFG
Metabolism. 2009; 58(8): 1059-
• Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AFG. Fenofibrate, simvastatin and their combination
in the management of dyslipidaemia in type 2 diabetic patients. Current Medical Research and Opinion (Curr Med Res Opin) 2009; 25(8): 1973–1983.
• Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AFG.
Metabolism. 2009; 59(6):
• Derosa G, Mereu R, Salvadeo SAT, D’Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AFG. Pioglitazone Metabolic Ef ect
in Metformin-Intolerant Obese Patients Treated with Sibutramine. Internal Medicine (Intern Med) 2009; 48(5): 265-271.
Pagina 6 - Curriculum vitae di Arrigo F.G. Cicero • Derosa G, Mereu R, D’Angelo A, Salvadeo SAT, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, Cicero AFG. Ef ect of pioglitazone
and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetics patients treated with sulphonylureas and metformin. Journal of Clinical Pharmacy and Therapeutics (J Clin Pharm Ther) 2010; 35(5): 565-579.
• Derosa G, Salvadeo SAT, D’Angelo A, Ferrari I, Mereu R, Palombo I, Maffioli P, Randazzo S, Cicero AFG. Metabolic effect of repaglinide or acarbose
when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Current Medical Research and Opinion (Curr Med Res Opin) 2009; 25(3): 607–615.
• Prandin MG, Cicero AFG, Dormi A, Veronesi M, Cosentino ER, Borghi C. Prospective evaluation of the effect of statins on blood pressure control in
hypertensive patients in clinical practise. Nutrition, Metabolism & Cardiovascular Diseases (Nutr Metab Cardiovasc Dis) 2009; 20(7):512-8.
• Sighinolfi MC, Micali S, Stefani SD, Cicero AFG, Cianci F, Giacometti M, Bianchi G
sian Journal of Andrology (Asian J Androl). 2009;11(4):493-7.
• Zenico T, Cicero AFG, Valmorri L, Mercuriali M, Bercovich E. Subjective effects of Lepidium Meyenii (Maca) extract on wellbeing and sexual
performances in patients with mild erectile dysfunction: a randomized, double-blind clinical trial. Andrologia 2009; 41(2): 95-99
Ardigò D, Bernini F, Borghi C, Calandra S, Cicero AFG, Favari E, Fellin R, Franzini L, Vigna GB, Zimetti F, Zavaroni I on behalf of the ADSL project
investigators. Advanced diagnostic support in lipidology project: role for phenotypic and functional evaluation of lipoproteins in dyslipidemias. Clinical Lipidology (Clin Lipidol) 2010; 5(3): 329-337
• Borghi C, Cicero AFG. Rationale for the use of fixed-dose combination in the management of hypertension: efficacy and tolerabilityof lercanidipine
plus enalapril. Clinical Drug Investigation (Clin Drug Invest) 2010; 30(12): 843-854.
• Bove M, Cicero AFG, Grandi E, Carnevali L, Gaddoni M, Noera G, Gaddi AV. Psychosocial factors and metabolic parameters: is there any
association in elderly people? The Massa Lombarda Project. Aging & Mental Health 2010; 14(7): 801-6.
• Cicero AFG, Derosa G, Borghi C. Red yeast rice and statin-intolerant patients. American Journal of Cardiology (Am J Cardiol) 2010; 105(10): 1504.
• Cicero AFG, Derosa G, Di Gregori V, Bove M, Gaddi AV, Borghi C. Omega 3 Polyunsaturated Fatty acids supplementation and blood pressure levels
in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clinical and Experimental Hypertension (Clin Exp Hypert) 2010;32(2):137-44
Cicero AFG, Dormi A, D’Addato S, Gaddi AV, Borghi C, on behalf of the Brisighella Heart Study Group. Long-term effect of a dietary education
program on postmenopausal cardiovascular risk and metabolic syndrome: The Brisighella Heart Study. Journal of Women’s Health (J Women Health) 2010; 19(1): 133-137.
• Cicero AFG, Ertek S. Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans. Archives of Medical
Science (Arch Med Sci) 2010; 6(4): 469-477.
• Cicero AFG, Rosticci M, Veronesi M, Bacchelli S, Strocchi E, Melegari C, Grandi E, Borghi C. Haemodynamic effects of Lactotripeptides from casein
hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, cross-over clinical trial. Journal of Medicinal Food (J Med Food) 2010; 13(6): 1363-1368.
• Cicero AFG. Body weight loss and blood pressure normalization: early intervention to “heal“ from hypertension? Hypertension Research (Hypert Res);
2010; 33(3):195-6.
Derosa G, D’Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palombo I, Maffioli P, Randazzo S, Cicero AFG. Oral glucose tolerance
test effects on endothelial inflammation markers in healthy subjects and diabetic patients. Hormones and Metabolism Research (Horm Metab Res) 2010;42(1): 8-13.
• Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AFG
Microvascular Research (Microvasc Res) 2010;79(2):144-9.
• Derosa G, Ferrari I, D'Angelo A, Salvadeo SA, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AFG
crovascular Research (Microvasc Res) 2010;80(1):110-5.
• Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AFG
ypertension Research (Hypert Res); 33(3):209-13. • Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AFG
abolism 2010;60(3):421-29
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, Fogari E, D'Angelo A, Cicero AFG
Hypertension Research (Hypertens Res) 2010;33(8):790-5.
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AFG
xpert Opinion in Pharmacotherapy (Expert Opin Pharmacother) 2010;11(12):1971-82.
• Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AFG.
iabetes Technology and Therapeutics. (Diabetes Technol Ther). 2010;12(3):233-40.
• Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AFG
ndocrine Journal (Endocr J). 2010 57(9): 777-786.
• Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AFG
nternal Medicine (Intern Med). 2010;49(16): 1717-1725.
Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AFG
ndamental and Clinical Pharmacology (Fundam Clin Pharmacol). 2010;25(5):642-51
• Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, Cicero AFG
ournal of Clinical Pharmacy and Therapeutics (J Clin Pharm Ther). 2010;35(5):565-579.
• Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AFG
ournal of Pharmacy and Pharmaceutical Sciences (J Pharm Pharm Sci). 2010;13(3):378-390.
• Ertek S, Cicero AFG, Cesur M, Akcil M, Altuner TK, Avcioglu U, Korkmaz ME. The severity of coronary atherosclerosis in diabetic and non-diabetic
metabolic syndrome patients diagnosed according to dif erent criteria and undergoing elective angiography. Acta Diabetologica (Acta Diabetol). 2011; 48(1): 21-27.
• Ertek S, Cicero AFG, Caglar O, Erdogan G. Relationship between serum zinc levels, thyroid hormones and thyroid volume following successful iodine
supplementation. Hormones 2010; 9(3): 262-268.
Pagina 7 - Curriculum vitae di Arrigo F.G. Cicero • Tomasoni L, Sitia S, Borghi C, Cicero AFG, Ceconi C, Cecaro F, Morganti A, Colonna VD, Guazzi M, Morricone L, Malavazos AE, Marino P,
Cavallino C, Shoenfeld Y, Turielutoimmunity Review (Autoimmun Rev). 2010; 9(12): 840-844.
• Akgul Ercan E, Ertek S, Is G, Caglar O, Oztas E, Cicero AFG, Alhan A, Cehreli S, Tore HF, Erdogan G.
ngiology. 2011; 62(7): 543-548.
• Borghi C, Cicero AFG, Degli Esposti D, Immordino V, Bacchelli S, Rizzo N, Santi F, Ambrosioni E. Hemodynamic and neurohumoral profile in
patients with dif erent types of hypertension in pregnancy. Internal and Emergency Medicine (Int Emerg Med) 2011; 6(3): 227-234.
Borghi C, Cosentino ER, Rinaldi ER, Brandolini C, Rimondi MC, Veronesi M, Cicero AFG, Dormi A, Pirodda A. Tinnitus in elderly patients and
prognosis of mild-to-moderate congestive heart failure: a cross-sectional study with a long-term extension of the clinical follow-up. BMC Medicine 2011;9:80 doi:10.1186/1741-7015-9-80
Cicero AFG, Derosa G, Maffioli P, Giovannini M, Grandi E, Borghi C. Influence of Metabolic Syndrome superposition on Familial Combined
Hyperlipoproteinemia cardiovascular complication rate. Archives of Medical Science (Arch Med Sci) 2011; In press • Cicero AFG, Dormi A, D’Addato S, Borghi C on behalf of the Brisighella Heart Study Staff. From risk factor assessment to cardiovascular disease risk
and mortality modification: the first 40 years of the Brisighella Heart Study. Clinical Lipidology (Clin Lipidol) 2011;6(3): 269-276.
• Cicero AFG, Ertek S. Hypertension and diabetes incidence: attention to the confounding factors. Hypertension Research (Hypert Res) 2011; 34(10):
• Cicero AFG, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with dif erent antihypertensive
drugs in clinical practice. Clinical and Experimental Hypertension (Clin Exp Hypert) 2011; In press PMID: 21967031 • Cicero AFG, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of
current available clinical trials. Journal of Human Hypertension (J Hum Hyper) 2011; 25(7): 425-436.
• Cicero AFG, Magni P, Lentini P, Ruscica M, Dozio E, Strollo F, Borghi C for the Brisighella Heart Study Staff. Sex hormones and adipokines in
healthy pre-menopausal, post-menopausal and elderly women, and in age-matched men: data from the Brisighella Heart Study. Journal of Endocrinological Investigation (J Endocrinol Invest) 2011; 34(7): e158-e162.
• Cicero AFG, Magni P, Moré M, Ruscica M, Dozio E, Steffani L, Borghi C, Strollo F, for the Brisighella Heart Study Staff. Adipokines and Sexual
Hormones Associated with the Components of the Metabolic Syndrome in Pharmacologically Untreated Subjects: Data from the Brisighella Heart Study. International Journal of Endocrinology (Int J Endocrinol) 2011; In press. doi:10.1155/2011/724816. • Cicero AFG, Rosticci M, Gerocarni B, Bacchelli S, Veronesi M, Strocchi E, Borghi C. Lactotripeptides effect on office and 24-hour ambulatory blood
pressure, blood pressure stress answer, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first degree hypertension: a randomized, double-blind, clinical trial. Hyertension Research (Hypert Res) 2011; 34(9): 1035-1040.
Derosa G, Maffioli P, Ferrari I, Fogari E, D'Angelo A, Palumbo I, Randazzo S, Bianchi L, Cicero AFG
uropean Journal of Pharmacology (Eur J Pharmacol.) 2011; 651(1-3): 240-250.
• Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, D'Angelo A, Cicero AFG
ypertension Research (Hypertens Res) 2011; 34(1): 145-151.
Derosa G, Maffioli P, D'Angelo A, Fogari E, Bianchi L, Cicero AFG
ournal of Diabetes Complications (J Diabetes Complications) 2011; 25(4): 258-266.
Derosa G, Cicero AFG, Fogari E, D'Angelo A, Bianchi L, Maffioli P.
ormones and Metabolism Research (Horm Metab Res.) 2011; 43(7): 505-512.
• Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P.
ournal of Clinical Pharmacy and Therapeutics (J Clin Pharm Ther) 2011 Aug 4. doi: 10.1111/j.1365-2710.2011.01280.x. • Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AFG
ournal of Clinical Pharmacology and Therapeutics (J Clin Pharm Ther). 2011; ;36(5): 592-601.
• Ertek S, Cicero AFG, Erdogan G. Relationship between calcium metabolism, insulin like growth factor-1 and pulse pressure in normotensive,
normolipidemic, non-diabetic subjects: a preliminary observation. Archives of Medical Science (Arch Med Sci) 2011; 7(5): 776-780.
• Pirodda A, Cicero AFG, Borghi C. Kidney disease and inner ear impairment: a simpler and closer pathogenic analogy? Internal and
Emergency Medicine (Intern Emerg Med) 2011; In press PMID:21968512 • Cicero AFG, Magni P, Moré M, Ruscica M, Ruscica M, Strollo F, Borghi C for the Brisighella Heart Study Staff. Metabolic syndrome, adipokines and
hormonal factors in pharmacologically untreated adult-elderly subjects from the Brisighella Heart Study historical cohort. Obesity Facts 2012; In press Cicero AFG, De Sando V, Parini A, Borghi C. Polyunsaturated Fatty Acids application in Internal medicine: beyond the established cardiovascular
effects. Archives of Medical Science (Arch Med Sci) 2011; In press • Cicero AFG, D’Addato S, Veronesi M, Rosticci M, Santi F, Dormi A, Borghi C. Relationship between blood pressure, cholesterolemia and serum
apolipoprotein B in a large population sample: the Brisighella Heart Study. Journal of Hypertension (J Hypert) 2012; In press Pagina 8 - Curriculum vitae di Arrigo F.G. Cicero

Source: http://www.studioaes.it/cv/Cicero_cv.pdf